Evidence map›Paper›PMID 40337478›Full record

ArticleMolecular therapy. Methods & clinical development2025

Mapping administration route-dependent transduction profiles of commonly used AAV variants in mice by barcode amplicon sequencing.

Sarah Abele, Gregorio Alanis-Lobato, Martin Oti, Werner Rust, Dragica Blazevic, Jenny Danner-Liskus, Christine Mayer, Gudrun Zimmermann, Kai Zuckschwerdt, Tanja Schönberger and 4 more

Abstract read
In one paragraph

Article in Molecular therapy. Methods & clinical development, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Sarah AbeleGlobal Drug Discovery Sciences, Boehringer Ingelheim Pharma GmbH & Co. KG, 88397 Biberach, Germany.
Gregorio Alanis-LobatoGlobal Computational Biology & Digital Sciences, Boehringer Ingelheim Pharma GmbH & Co. KG, 88397 Biberach, Germany.
Martin OtiGlobal Computational Biology & Digital Sciences, Boehringer Ingelheim Pharma GmbH & Co. KG, 88397 Biberach, Germany.
Werner RustGlobal Computational Biology & Digital Sciences, Boehringer Ingelheim Pharma GmbH & Co. KG, 88397 Biberach, Germany.
Dragica BlazevicEye Health & Research Beyond Borders, Boehringer Ingelheim Pharma GmbH & Co. KG, 88397 Biberach, Germany.
Jenny Danner-LiskusGlobal Drug Discovery Sciences, Boehringer Ingelheim Pharma GmbH & Co. KG, 88397 Biberach, Germany.
Christine MayerGlobal Drug Discovery Sciences, Boehringer Ingelheim Pharma GmbH & Co. KG, 88397 Biberach, Germany.
Gudrun ZimmermannGlobal Drug Discovery Sciences, Boehringer Ingelheim Pharma GmbH & Co. KG, 88397 Biberach, Germany.
Kai ZuckschwerdtGlobal Drug Discovery Sciences, Boehringer Ingelheim Pharma GmbH & Co. KG, 88397 Biberach, Germany.
Tanja SchönbergerGlobal Drug Discovery Sciences, Boehringer Ingelheim Pharma GmbH & Co. KG, 88397 Biberach, Germany.
Peter GrossGlobal Drug Discovery Sciences, Boehringer Ingelheim Pharma GmbH & Co. KG, 88397 Biberach, Germany.
Charlotte LemppGlobal Drug Discovery Sciences, Boehringer Ingelheim Pharma GmbH & Co. KG, 88397 Biberach, Germany.
Stefan MichelfelderEye Health & Research Beyond Borders, Boehringer Ingelheim Pharma GmbH & Co. KG, 88397 Biberach, Germany.
Benjamin StrobelGlobal Drug Discovery Sciences, Boehringer Ingelheim Pharma GmbH & Co. KG, 88397 Biberach, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The tissue transduction profiles and transgene expression efficiencies of adeno-associated viruses (AAVs) depend not only on the utilized capsid and dose but also on the administration route. Yet, despite the plethora of available natural and capsid-engineered variants, a comprehensive evaluation of the administration route dependency of AAV tropism has been lacking so far. Therefore, we here compared transduction and transgene expression profiles for 34 well-known AAV capsids following intravenous (i.v.) and intraperitoneal (i.p.) injection in male C57BL/6 mice by multiplexed biodistribution analyses based on AAV genome-barcoding. Readout on viral genome and transcript level confirmed pronounced liver targeting by most AAV variants after i.v. administration, as well as known tissue tropism for benchmark capsids (e.g., AAV-PHP.eB: brain and AAV2-ESGHGYF: lung). In contrast, i.p. administration generally decreased liver targeting, while concurrently increasing expression in other abdominal organs in a capsid-specific fashion. For example, AAV6.2 and AAV-DJ, which showed almost exclusive liver transduction after i.v. administration, displayed differential biodistribution profiles with enhanced expression in the diaphragm, adipose tissue, and pancreas when administered intraperitoneally. In summary, our data guide study design by enabling the selection of optimal vector and administration route combinations for refined tissue targeting approaches in preclinical

Indexed as

3RAAV biodistributionadipose tissue transductionbarcodingintraperitonealintravenousliver detargetingNGSpancreas transductiontissue tropism

Identifiers

PMID40337478
PMCPMC12056398

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.